Seattle Genetics (NASDAQ: [[ticker:SGEN]]), the Bothell, WA-based developer of targeted cancer drugs, said today that Eric Dobmeier has been promoted from chief business officer to chief operating officer. Dobmeier, who joined the company in 2002, has overseen the company’s efforts to license out its technology for linking antibodies to toxins that make them more potent against cancer. The biggest deal on his watch has been the alliance with Millennium: The Takeda Oncology Company, in which the companies divvied up commercial rights to brentuximab vedotin (Adcetris), as a new treatment for rare lymphomas.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
